Skip to main content

Advertisement

SpringerLink
Log in

Diagnostic performance of a new vimentin-derived ACPA (CCP high sensitive) in patients with rheumatoid arthritis

  • Original Article
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

Autoantibodies are a common feature of rheumatoid arthritis (RA), and their detection is used as a diagnostic tool in medical practice. Rheumatoid factor (RF) and/or anti-citrullinated protein antibodies (ACPA) detection in patients’ sera are now included in 2010 ACR/EULAR criteria for RA diagnosis. In this study, we evaluated a new vimentin-derived ACPA ELISA, the anti-cyclic citrullinated peptide high sensitive (CCP hs) test, and we compared its performance with the RF IgM and anti-CCP3 tests on a French multicenter cohort of 84 RA patients, 107 non-RA patients and 100 healthy controls. Sensitivities for RA diagnosis were 71.4, 84.5 and 64.3 % and specificities were 88.4, 86.9 and 87.3 % for CCP hs, CCP3 and RF IgM, respectively. There was a moderate correlation between CCP hs and CCP3 titers (Pearson’s r = 0.43; p < 0.0001). These results support the contention that anti-CCP hs antibodies are new reliable ACPA with high specificity for RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Machado P, Castrejon I, Katchamart W, Koevoets R, Kuriya B, Schoels M, et al. Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2011;70:15–24. doi:10.1136/ard.2010.130625.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Van Nies JAB, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AHM. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts. Ann Rheum Dis. 2015;74:806–12. doi:10.1136/annrheumdis-2014-206047.

    Article  PubMed  Google Scholar 

  3. Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum. 2006;55:864–72. doi:10.1002/art.22353.

    Article  PubMed  Google Scholar 

  4. Darrah E, Andrade F. Editorial: citrullination, and carbamylation, and malondialdehyde-acetaldehyde! Oh my! Entering the forest of autoantigen modifications in rheumatoid arthritis. Arthritis Rheumatol. 2015;67:604–8. doi:10.1002/art.38970.

    Article  CAS  PubMed  Google Scholar 

  5. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81. doi:10.1002/art.27584.

    Article  PubMed  Google Scholar 

  6. Van Venrooij WJ, van Beers JJBC, Pruijn GJM. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol. 2011;7:391–8. doi:10.1038/nrrheum.2011.76.

    Article  PubMed  Google Scholar 

  7. Hayem G, Chazerain P, Combe B, Elias A, Haim T, Nicaise P, et al. Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol. 1999;26:7–13.

    CAS  PubMed  Google Scholar 

  8. Vossenaar ER, Després N, Lapointe E, van der Heijden A, Lora M, Senshu T, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther. 2004;6:R142–50. doi:10.1186/ar1149.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bang H, Egerer K, Gauliard A, Lüthke K, Rudolph PE, Fredenhagen G, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 2007;56:2503–11. doi:10.1002/art.22817.

    Article  CAS  PubMed  Google Scholar 

  10. Qin X, Deng Y, Xu J, Li T-J, Li S, Zhao J-M. Meta-analysis: diagnostic value of serum anti-mutated citrullinated vimentin antibodies in patients with rheumatoid arthritis. Rheumatol Int. 2011;31:785–94. doi:10.1007/s00296-009-1343-3.

    Article  CAS  PubMed  Google Scholar 

  11. Infantino M, Manfredi M, Meacci F, Sarzi-Puttini P, Ricci C, Atzeni F, et al. Anti-citrullinated peptide antibodies and rheumatoid factor isotypes in the diagnosis of rheumatoid arthritis: an assessment of combined tests. Clin Chim Acta Int J Clin Chem. 2014;436:237–42. doi:10.1016/j.cca.2014.05.019.

    Article  CAS  Google Scholar 

  12. Coenen D, Verschueren P, Westhovens R, Bossuyt X. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem. 2007;53:498–504. doi:10.1373/clinchem.2006.078063.

    Article  CAS  PubMed  Google Scholar 

  13. Szekanecz Z, Lakos G. Rheumatoid arthritis diagnosis with antimutated citrullinated vimentin ELISA by Orgentec Diagnostika. Expert Opin Med Diagn. 2008;2:1083–90. doi:10.1517/17530059.2.9.1083.

    Article  PubMed  Google Scholar 

  14. Swart A, Burlingame RW, Gürtler I, Mahler M. Third generation anti-citrullinated peptide antibody assay is a sensitive marker in rheumatoid factor negative rheumatoid arthritis. Clin Chim Acta Int J Clin Chem. 2012;414:266–72. doi:10.1016/j.cca.2012.09.015.

    Article  CAS  Google Scholar 

  15. Harich R, Roger C, Garnier L, Bienvenu J, Fabien N. Comparison of anti-CCP autoantibodies measurement by ELISA and a bead-based assay in a large patient cohort. Clin Biochem. 2014;47:485–8. doi:10.1016/j.clinbiochem.2014.02.010.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Orgentec SAS, Trappes, France, and Orgentec Diagnostika GmbH, Mainz, Germany, for supplying RF and CCP hs ® reagents. We would like to thank Michel Khrestchatisky for careful reading of the manuscript and helpful comments and suggestions.

Author information

Authors and Affiliations

  1. Service d’Immunologie, Pôle de Biologie, Hôpital de la Conception, Assistance Publique-Hôpitaux de Marseille, 147, Bd Baille, 13005, Marseille, France

    Daniel Bertin & Sophie Desplat-Jégo

  2. NICN UMR 7259, Aix-Marseille Université, CNRS, 13916, Marseille, France

    Daniel Bertin & Sophie Desplat-Jégo

  3. Institut d’Immunologie – Centre de Biologie Pathologie et Génétique, CHRU Lille, 59037, Lille, France

    Sylvain Dubucquoi & Anne-Sophie Deleplancque

  4. LIRIC, UMR 995, INSERM, 59000, Lille, France

    Sylvain Dubucquoi

  5. EA 2686, Université Lille Nord de France, 59000, Lille, France

    Sylvain Dubucquoi

  6. Laboratoire d’Immunologie, Plateau Technique de Biologie, CHU Dijon, 21000, Dijon, France

    Daniela Lakomy

Authors
  1. Daniel Bertin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sylvain Dubucquoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniela Lakomy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anne-Sophie Deleplancque
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sophie Desplat-Jégo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Bertin.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bertin, D., Dubucquoi, S., Lakomy, D. et al. Diagnostic performance of a new vimentin-derived ACPA (CCP high sensitive) in patients with rheumatoid arthritis. Immunol Res 64, 455–460 (2016). https://doi.org/10.1007/s12026-015-8690-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-015-8690-9

Keywords

Search

Navigation